Diabetologia 66 (10), 17651779 (2023) B
These policies reflect both scientific caution and operational liability management rather than definitive evidence of harm from GLP-1-containing plasma
The hearing will discuss expert testimony on the diagnosis of gastroparesis, a central issue in federally filed lawsuits
Therefore, although several studies have been conducted, additional multiple-centered RCTs are needed to analyze different parts of bone tissue in patients with different metabolic statuses, being treated with different versions of GLP-1RAs
These can include: Nausea, Vomiting, Diarrhea, Stomach upset or pain, Bloating, Headache, Skin rash or allergic reactions (itching, hives, swelling), Fatigue